Table 1.
Patients’ demographic and tumour characteristics treated with IRE (2015–2020)
| Parameter | IRE-treated population (n = 26) |
|---|---|
| Age | |
| Mean +/- SD | 65 (+/-11.4) |
| Median and range | 67 (32–81) |
| Sex | Male (17) female (9) |
| Tumour characteristics | (n = 30) |
| Mean +/- SD (cm) | 2.5 +/- 0.93 |
| Median and range (cm) | 2.5 (1–4) |
| Size < 2 cm | 7 (23%) |
| Size > or = 2 cm | 23 (77%) |
| R.E.N.A.L. score, median (SD) | 6 (1.97) |
| No. left vs. right (%) | 15 (50%) vs 15 (50%) |
| Tumour polarity | |
| Upper (%) | 4 (13.3%) |
| Interpolar (%) | 9 (30%) |
| Lower (%) | 17 (57%) |
| IRE treatment time (min), median (SD) | 80 (24.2) |
| No. of probes, mean (SD) | 5 (1.37) |
| Histopathology | |
| Clear cell RCC (%) | 19 (63%) |
| Papillary RCC (%) | 5 (16%) |
| Chromophobe RCC (%) | 2 (7%) |
| Eosinophilic RCC (%) | 2 (7%) |
| VHL with history biopsied proven clear cell RCC | 2 (7%) |
| GFR (ml/min/1.73m2) | |
| Pre-IRE, mean (SD) | 68 (17) |
| Post-IRE, mean (SD) | 60 (19) |
| % change, mean (SD) | - 13 (16) |